Aegerion Pharmaceuticals (NASDAQ:AEGR) had its price objective raised by Needham & Company from $50.00 to $100.00 in a research report released on Monday morning, AnalystRatings.Net reports. Needham & Company currently has a buy rating on the stock.
Aegerion Pharmaceuticals (NASDAQ: AEGR) traded up 1.12% on Monday, hitting $77.41. Aegerion Pharmaceuticals has a 52-week low of $12.87 and a 52-week high of $81.00. The stock’s 50-day moving average is currently $70.54. The company’s market cap is $2.231 billion.
AEGR has been the subject of a number of other recent research reports. Analysts at Cowen and Company raised their price target on shares of Aegerion Pharmaceuticals to $83.50 in a research note to investors on Tuesday, July 9th. They now have an outperform rating on the stock. Separately, analysts at JP Morgan Cazenove raised their price target on shares of Aegerion Pharmaceuticals to $88.00 in a research note to investors on Thursday, June 13th. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Aegerion Pharmaceuticals to $88.00 in a research note to investors on Wednesday, June 12th. They noted that the move was a valuation call.
Seven analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and an average price target of $79.04.
Aegerion Pharmaceuticals, Inc (NASDAQ: AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.